Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy

• Main Authors: Ingo Roehl (Author), Stephan Seiffert (Author), Celia Brikh (Author), Jonathan Quinet (Author), Catherine Jamard (Author), Nadine Dorfler (Author), Jennifer A. Lockridge (Author), Lucyna Cova (Author), Andrew Vaillant (Author)
• Format: Book
• Published: Elsevier, 2017-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

REP 2139 is a nucleic acid polymer (NAP) currently under clinical development for chronic hepatitis B (HBV) therapy. This preclinical study investigated different REP 2139 analogs that would display reduced accumulation in the serum and tissues, while retaining an antiviral effect against HBV infect...